Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) Gross Profit: 2009-2025

Historic Gross Profit for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to $698.6 million.

  • UNITED THERAPEUTICS's Gross Profit rose 4.93% to $698.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year increase of 13.29%. This contributed to the annual value of $2.6 billion for FY2024, which is 24.04% up from last year.
  • Latest data reveals that UNITED THERAPEUTICS reported Gross Profit of $698.6 million as of Q3 2025, which was down 1.74% from $711.0 million recorded in Q2 2025.
  • In the past 5 years, UNITED THERAPEUTICS's Gross Profit ranged from a high of $711.0 million in Q2 2025 and a low of $356.1 million during Q1 2021.
  • Moreover, its 3-year median value for Gross Profit was $621.0 million (2024), whereas its average is $608.9 million.
  • Data for UNITED THERAPEUTICS's Gross Profit shows a peak YoY skyrocketed of 33.04% (in 2024) over the last 5 years.
  • UNITED THERAPEUTICS's Gross Profit (Quarterly) stood at $380.6 million in 2021, then grew by 13.69% to $432.7 million in 2022, then climbed by 25.65% to $543.7 million in 2023, then climbed by 23.46% to $665.8 million in 2024, then climbed by 4.93% to $698.6 million in 2025.
  • Its last three reported values are $698.6 million in Q3 2025, $711.0 million for Q2 2025, and $701.9 million during Q1 2025.